An older diabetes treatment called lixisenatide resulted in less progression of motor disability after 12 months in patients in an early stage of the disease Erin Clack is a Staff Editor for PEOPLE.

A recent study published in The New England Journal of Medicine has demonstrated that lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may slow the progression of motor disability in ...

NEW YORK--(BUSINESS WIRE)--The Larry G. Gluck Division of ALS Research, located at the Tisch MS Research Center of New York, has published research in Brain Communications identifying apolipoprotein B ...

Changes in motor units closely reflect disease severity in people with spinal muscular atrophy (SMA), suggesting potential ...

DUARTE, Calif., Aug. 20, 2025 /PRNewswire/ -- A groundbreaking study has revealed something remarkable about premature babies fed Prolacta Bioscience's Exclusive Human Milk Diet (EHMD): Despite being ...

Please provide your email address to receive an email when new articles are posted on . Students with a chronic illness, sensory or motor disability or multiple disabilities often experience ...

Patients with early Parkinson disease who received lixisenatide had a decrease in motor disability progression, but they also experienced gastrointestinal side effects. Lixisenatide vs placebo is ...